Patisiran (Onpattro™)

Onpattro (patisiran) is covered for adults for the FDA‑approved indication of polyneuropathy due to hereditary transthyretin‑mediated amyloidosis; off‑label uses and patients with a history of liver transplantation are excluded. Coverage requires genetic confirmation of hATTR, documented symptomatic polyneuropathy (e.g., history/exam, EMG/NCS), age ≥18, prior or current trial of at least one specified symptomatic agent (gabapentin‑type, duloxetine, or a tricyclic), prescription by or consultation with a neurologist/geneticist/amyloidosis specialist, and is authorized for 12 months at 0.3 mg/kg IV every 3 weeks (max 30 mg).

"There is no history of liver transplantation."

Sign up to see full coverage criteria, indications, and limitations.